Alnylam Pharmaceuticals, Inc. research snapshot
ALNY AI stock analysis currently reads Alnylam Pharmaceuticals, Inc. as a commercial-stage RNAi therapeutics leader with fast AMVUTTRA-driven revenue growth, first full-year GAAP profitability in 2025, a deep late-stage pipeline, and meaningful concentration and valuation risk. At the July 9, 2026 data cutoff, ALNY traded near $319.83 with an implied market capitalization of about $42.70 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$319.83
Market cap
$42.70 billion
AI score
66 / 100
Rating
High-growth RNAi leader, valuation-sensitive
Trend status
Fundamental growth strong, technical trend mixed after pullback
Data cutoff (updated weekly)
July 9, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alnylam sells RNAi medicines led by AMVUTTRA and ONPATTRO in TTR amyloidosis, plus GIVLAARI and OXLUMO in rare diseases, with collaboration and royalty revenue adding another stream. | High |
| Moat | The moat comes from RNAi science, delivery know-how, patents, clinical evidence, specialist relationships, manufacturing scale, and a growing commercial base in TTR disease. | Medium-high |
| Management | Yvonne Greenstreet and the team have executed the AMVUTTRA ATTR-CM launch and profitability turn, but future judgment rests on pipeline productivity and disciplined reinvestment. | Medium-high |
| Financial trend | FY2025 revenue rose to $3.714 billion, FY2025 GAAP net income reached $313.7 million, and Q1 2026 total net product revenue reached $1.036 billion. | High |
| Valuation | At $319.83, ALNY traded near 137.3x FY2025 GAAP EPS, 63.0x FY2025 non-GAAP EPS, 91.0x FY2025 free cash flow per share, and about 10.0x TTM revenue per share. | Medium-high |
| Technical trend | Price was above several shorter moving-average references but below some longer technical references, with support near $293 to $298 and resistance near $400 to $402. | Medium |
| Risk level | Main risks are AMVUTTRA concentration, ATTR-CM competition from Pfizer and BridgeBio, clinical readout volatility, pricing and discount scrutiny, and rich valuation. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks move around trial, payer, regulatory, and competition news. | High data confidence |
| Investment certainty | Medium-low certainty. ALNY has a valuable RNAi platform, but the stock needs sustained product growth and pipeline execution to justify the current multiple. | Medium-low |
ALNY AI stock forecast
The ALNY AI stock forecast uses scenario math around the $319.83 quote and FY2025 non-GAAP EPS of $5.08. The audited three-year framework produced a bullish area near $446, a base area near $270, and a bearish area near $147 before any future dilution, acquisitions, or major clinical events.
$430 to $460
More likely if AMVUTTRA keeps scaling in ATTR-CM, total 2026 product revenue lands near or above the $4.9 billion to $5.3 billion guidance range, nucresiran and zilebesiran data de-risk the pipeline, and investors keep paying a premium growth multiple.
$260 to $285
More likely if revenue growth stays strong but valuation compresses as ALNY invests heavily in R&D and SG&A, competition limits TTR upside, and the market values the company closer to a mature profitable biotech.
$140 to $155
More likely if AMVUTTRA growth slows, ATTR-CM competition improves access or outcomes, payer pressure cuts net price, clinical readouts disappoint, or the stock rerates toward a lower earnings multiple.
ALNY AI technical analysis
ALNY AI technical analysis is mixed as of the July 9, 2026 cutoff. StockAnalysis listed ALNY near $319.83 on July 8, ChartMill flagged support around $293.11 to $297.52 and resistance around $400.36 to $402.22, while other technical sources showed moving-average signals split between short-term support and longer-term caution.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $319.83 | StockAnalysis real-time snapshot used for July 9, 2026 research and market cap math. |
| Near support | $293 to $298 | ChartMill listed a support zone from $293.11 to $297.52 formed by multiple trend references. |
| Secondary support | $283 to $284 | Intellectia listed immediate support near $283.54, which helps define downside risk if the $293 area fails. |
| Moving averages | Mixed | Investing.com showed 50-day and 200-day moving averages near $304.95 and $295.24 as Buy references, while other sources showed the 50-day below a higher 200-day average. |
| Resistance | $400 to $402 | ChartMill listed the first major resistance zone around $400.36 to $402.22. |
| Higher resistance | $420 to $428, then $441 | ChartMill listed another resistance zone near $420.33 to $428.23 and a weekly trend-line resistance near $441.30. |
| Momentum | Recovering but not clean | The pullback from late-2025 highs leaves ALNY with a rebound setup, but the signal is not confirmed while price remains below the higher resistance bands. |
| Volume | Event-sensitive biotech volume | Volume should be compared with earnings, clinical readouts, FDA updates, payer news, and competitive ATTR-CM headlines. |
| Volatility | High for a profitable growth biotech | Expect larger moves around AMVUTTRA demand, nucresiran, zilebesiran, mivelsiran, ALN-6400, and drug-pricing news. |
| Invalidation | Close below $293, then $283 | A decisive break below the $293 support zone would weaken the swing setup. A break below $283 would require a deeper thesis review. |
ALNY AI trading strategy
The ALNY AI trading strategy is a rules-based framework for a high-growth biotechnology stock with product concentration, pipeline optionality, and event risk. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical or regulatory event checks.
Watch for ALNY to hold above the $293 to $298 support zone, reclaim the higher moving-average references, and move toward the $400 to $402 resistance area with confirming volume and no negative product or trial news.
A close below $293 should invalidate the short-term swing setup. A close below $283 should force a full review of AMVUTTRA growth, pipeline news, and valuation assumptions.
If ALNY pulls back toward support without a new clinical, payer, or competitive problem, compare the price move with Q1 product growth, 2026 revenue guidance, and cash generation.
Do not treat every pullback as mean reversion. Biotech support levels can fail fast when clinical readouts, reimbursement, or product concentration risks change.
Track AMVUTTRA and ONPATTRO TTR revenue, GIVLAARI, OXLUMO, Leqvio royalties, 2026 product revenue guidance, nucresiran, zilebesiran, mivelsiran, ALN-6400, cash and investments, debt, and share dilution.
Reduce confidence if valuation depends mainly on a premium multiple rather than durable TTR growth, successful pipeline readouts, and expanding operating cash flow.
Investment research summary
Alnylam turns RNA interference science, delivery chemistry, clinical proof, regulatory approvals, and rare-disease commercial execution into medicine revenue for diseases where gene silencing can change outcomes.
The moat is strongest where RNAi intellectual property, GalNAc delivery, long dosing intervals, specialist trust, manufacturing know-how, and clinical trial evidence reinforce each other. It narrows if rivals match efficacy, convenience, access, or price.
The thesis fails if AMVUTTRA growth slows faster than expected, ATTR-CM competition takes share, payer and pricing pressure reduces net revenue, clinical programs disappoint, or valuation multiples compress before earnings scale.
Management has converted a platform story into a profitable commercial company, but the next test is capital allocation across internal R&D, manufacturing capacity, partnerships, and shareholder dilution.
RNAi sits inside a long-term shift toward genetic medicines and precision therapies. The opportunity is large, but adoption depends on durable outcomes, safety, access, manufacturing cost, and competition from small molecules, antibodies, and gene-based approaches.
ALNY is priced for continued high growth and pipeline success. Margin of safety is limited if investors require a lower multiple, but improves if product revenue guidance is exceeded and late-stage data expands the addressable market.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALNY price | $319.83 | StockAnalysis market cap snapshot | July 9, 2026 |
| Market capitalization | $42.70 billion, verified as $319.83 x 133.51 million shares | financial_rigor.py market cap verification and StockAnalysis | July 9, 2026 |
| FY2025 revenue | $3.713937 billion | Alnylam FY2025 release, Alnylam financial statements, Macrotrends, and StockAnalysis | July 9, 2026 |
| FY2025 GAAP net income | $313.747 million | Alnylam FY2025 release and Macrotrends cross-check | July 9, 2026 |
| FY2025 cash and short-term investments | $2.908 billion, with total debt of $2.698 billion at year-end 2025 | Alnylam financial statements and Macrotrends cash-on-hand cross-check | July 9, 2026 |
| FY2025 net product revenue | $2.987 billion, up 81% year over year | Alnylam FY2025 earnings release | July 9, 2026 |
| Q1 2026 total net product revenue | $1.036 billion, up 121% year over year | Alnylam Q1 2026 earnings release | July 9, 2026 |
| Q1 2026 GAAP net income and diluted EPS | $205.991 million net income and $1.51 diluted EPS | Alnylam Q1 2026 earnings release | July 9, 2026 |
| 2026 product revenue guidance | $4.9 billion to $5.3 billion total net product revenue | Alnylam Q1 2026 earnings release | July 9, 2026 |
| Technical support and resistance | Support $293.11 to $297.52, resistance $400.36 to $402.22 | ChartMill technical analysis | July 9, 2026 |
This ALNY AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 9, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
